One Man’s Shares His Personal Tips About Having Provenge To Treat His Advanced Prostate Cancer

The following was posted on the Malecare Advanced Prostate Cancer Health Unlocked online support group.  I have received permission to reprint it here because it might be helpful to some of you. FYI-    Provenge is a cancer vaccine that helps to mobilize your own immune system to your prostate cancer.  It is currently only approved in the United States for men who castrate resistant. It is administered by first removing a bag of your white blood cells, sending them off to a factory in Seale Beacj Calif. where the white cells (T cells) are altered by having a protein [...]

By | December 9th, 2016|Drugs & Treatments, General Information, immunotherapy, Provenge|0 Comments

It Is Clear Who Should Take Provenge And Who Should Not

Provenge, despite its demonstrated survival advantage continues to be knocked as a viable treatment for men with castrate resistant prostate cancer. Why is this the case? First,  Provenge does not affect the PSA. Most men will continue to see their PSA rise, as well as their disease progress based on scans, while they take the treatment. Remember, the total treatment time is one month long. Many of our other treatments do affect the PSA, so many men believe that Provenge is nothing more than a placebo. However, I have been saying that not all men are in fact candidates for [...]

More On The Efficacy Of Sipuleucel-T (Provenge) – It Works

Despite its approval five years ago sipuleucel-T (Provenge) remains one of the most controversial treatments available for men with castrate resistant metastatic prostate cancer (mCRPC). Provenge has its advocates (Full Disclosure- I am) and it has many detractors. The detractors argue that it doesn’t work and they hang their hat on the argument that it doesn’t affect the PSA nor disease progression, which is true. Additionally, there was an earlier, now debunked, argument that there was fraud involved in the phase 3 IMPACT trial that derived the data that led to Provenge’s being approved by the FDA. Since Provenge’s approval [...]

The Twists and Turns For Provenge

It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in men with biochemically-recurrent prostate cancer (BRPC). This finding, along with data from the ongoing Phase IV registry PROCEED trial, are being presented at the 2015 Genitourinary Cancers Symposium (ASCO GU) conference. The STAND study is a randomized, Phase II trial that consisted of two patient study groups designed to eventually allow the possible expansion of the FDA approval for Provenge to men who are still [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー